Merck's (MRK) Tredaptive Miss May Benefit Amarin (AMRN) - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall St gains as chips recover; megacap earnings in focus
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Wall St gains as chips recover; megacap earnings in focus
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threat
- IREN raises 2026 revenue target to $4bn after $2.8bn in contracts
Merck (MRK) Says HPS2-THRIVE Missed Primary Endpoint
December 20, 2012 8:32 AM ESTMerck (NYSE: MRK), known outside the United States and Canada as MSD, today announced that the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE(extended-release niacin/laropiprant) did not meet its primary endpoint. Merck and the investigators are informing regulatory agencies of these results. The company is also preparing communications to health care providers in countries where the medicine is currently available, and will continue to work with regulators to provide updated information to health care providers. Based on the current understanding of these... More
